Stock listing
NASDAQ:PYXS Pyxis Oncology, Inc. Stock
Home listing (NASDAQ) of Pyxis Oncology, Inc.
Follow Pyxis Oncology, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:PYXS
$1.81 USD +0.13 (+7.7%)
Close on Nov 20, 2026
- Day range
- $1.70 – $1.99 USDNov 20, 2026
- Volume
- 3.05M sharesNov 20, 2026
- Market cap
- $216.5M USDAt the close on Nov 20, 2026 · price × 119.6M shares outstanding
- 52-week range
- $1.03 – $5.55 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.51M USDMedian day 729,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PYXS · Home | $1.81 USD | +0.13 (+7.7%) | 3,046,358 | $1.70 | $1.99 | $1.70 | $1.68 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PYXS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.81 | +0.13 | +7.7% | $1.70 | $1.99 | $1.70 | 3,046,358 | |
| $1.68 | +0.27 | +19.1% | $1.41 | $1.695 | $1.35 | 1,804,987 | |
| $1.41 | -0.03 | -2.1% | $1.45 | $1.48 | $1.38 | 765,152 | |
| $1.44 | +0.03 | +2.1% | $1.48 | $1.53 | $1.34 | 1,435,539 | |
| $1.41 | -0.17 | -10.8% | $1.55 | $1.56 | $1.41 | 847,998 | |
| $1.58 | 0.00 | 0.0% | $1.57 | $1.60 | $1.51 | 359,400 | |
| $1.58 | -0.06 | -3.7% | $1.62 | $1.625 | $1.52 | 1,003,100 | |
| $1.64 | +0.01 | +0.6% | $1.63 | $1.68 | $1.59 | 665,200 | |
| $1.63 | -0.07 | -4.1% | $1.66 | $1.735 | $1.59 | 592,600 | |
| $1.70 | +0.04 | +2.4% | $1.70 | $1.795 | $1.67 | 880,900 | |
| $1.66 | +0.05 | +3.1% | $1.62 | $1.74 | $1.62 | 560,400 | |
| $1.61 | -0.05 | -3.0% | $1.64 | $1.675 | $1.50 | 1,149,600 | |
| $1.66 | +0.02 | +1.2% | $1.67 | $1.71 | $1.565 | 923,000 | |
| $1.64 | -0.05 | -3.0% | $1.72 | $1.76 | $1.62 | 645,800 | |
| $1.69 | -0.12 | -6.6% | $1.825 | $1.86 | $1.625 | 897,200 | |
| $1.81 | -0.08 | -4.2% | $1.88 | $1.885 | $1.78 | 685,700 | |
| $1.89 | -0.09 | -4.5% | $1.98 | $1.992 | $1.88 | 697,200 | |
| $1.98 | +0.14 | +7.6% | $1.83 | $1.99 | $1.80 | 728,100 | |
| $1.84 | +0.15 | +8.9% | $1.70 | $1.85 | $1.68 | 1,183,200 | |
| $1.69 | +0.01 | +0.6% | $1.66 | $1.72 | $1.634 | 645,800 | |
| $1.68 | -0.03 | -1.8% | $1.70 | $1.71 | $1.63 | 626,700 | |
| $1.71 | -0.05 | -2.8% | $1.74 | $1.79 | $1.695 | 557,500 | |
| $1.76 | -0.08 | -4.3% | $1.85 | $1.87 | $1.75 | 500,400 | |
| $1.84 | +0.08 | +4.5% | $1.76 | $1.90 | $1.73 | 1,110,300 | |
| $1.76 | +0.08 | +4.8% | $1.69 | $1.79 | $1.675 | 1,016,400 | |
| $1.68 | -0.12 | -6.7% | $1.79 | $1.79 | $1.66 | 908,200 | |
| $1.80 | +0.01 | +0.6% | $1.79 | $1.84 | $1.75 | 545,700 | |
| $1.79 | -0.06 | -3.2% | $1.82 | $1.88 | $1.735 | 1,558,200 | |
| $1.85 | -0.16 | -8.0% | $1.99 | $1.998 | $1.85 | 900,400 | |
| $2.01 | -0.02 | -1.0% | $2.03 | $2.08 | $1.99 | 505,700 | |
| $2.03 | +0.04 | +2.0% | $1.99 | $2.06 | $1.98 | 950,400 | |
| $1.99 | -0.02 | -1.0% | $2.03 | $2.03 | $1.902 | 1,097,100 | |
| $2.01 | -0.01 | -0.5% | $2.02 | $2.086 | $2.00 | 957,800 | |
| $2.02 | -0.22 | -9.8% | $2.22 | $2.22 | $2.00 | 1,403,400 | |
| $2.24 | +0.10 | +4.7% | $2.12 | $2.26 | $2.05 | 1,515,100 | |
| $2.14 | -0.05 | -2.3% | $2.21 | $2.31 | $2.10 | 1,996,600 | |
| $2.19 | -0.14 | -6.0% | $2.31 | $2.31 | $2.19 | 2,602,300 | |
| $2.33 | -0.57 | -19.7% | $2.375 | $2.41 | $2.12 | 8,149,500 | |
| $2.90 | 0.00 | 0.0% | $2.94 | $2.94 | $2.83 | 335,500 | |
| $2.90 | +0.04 | +1.4% | $2.81 | $2.91 | $2.75 | 368,100 | |
| $2.86 | -0.06 | -2.1% | $2.91 | $2.92 | $2.785 | 609,700 | |
| $2.92 | -0.30 | -9.3% | $3.22 | $3.25 | $2.86 | 875,300 | |
| $3.22 | -0.135 | -4.0% | $3.36 | $3.36 | $3.20 | 433,600 | |
| $3.355 | +0.165 | +5.2% | $3.21 | $3.405 | $3.19 | 479,800 | |
| $3.19 | -0.14 | -4.2% | $3.38 | $3.38 | $3.19 | 632,800 | |
| $3.33 | -0.08 | -2.3% | $3.38 | $3.44 | $3.33 | 563,900 | |
| $3.41 | +0.07 | +2.1% | $3.43 | $3.472 | $3.339 | 476,700 | |
| $3.34 | +0.01 | +0.3% | $3.34 | $3.42 | $3.32 | 639,900 | |
| $3.33 | -0.10 | -2.9% | $3.40 | $3.42 | $3.24 | 489,600 | |
| $3.43 | +0.22 | +6.9% | $3.21 | $3.515 | $3.21 | 699,500 | |
| $3.21 | -0.06 | -1.8% | $3.31 | $3.42 | $3.07 | 1,129,400 | |
| $3.27 | -0.11 | -3.3% | $3.42 | $3.437 | $3.18 | 738,500 | |
| $3.38 | -0.51 | -13.1% | $3.48 | $4.12 | $3.132 | 4,345,200 | |
| $3.89 | 0.00 | 0.0% | $4.00 | $4.15 | $3.845 | 1,375,600 | |
| $3.89 | +0.325 | +9.1% | $3.53 | $4.05 | $3.515 | 2,230,600 | |
| $3.565 | -0.185 | -4.9% | $3.71 | $3.74 | $3.45 | 812,100 | |
| $3.75 | +0.31 | +9.0% | $3.45 | $3.77 | $3.435 | 730,300 | |
| $3.44 | +0.20 | +6.2% | $3.24 | $3.57 | $3.18 | 590,200 | |
| $3.24 | +0.01 | +0.3% | $3.20 | $3.28 | $3.05 | 469,500 | |
| $3.23 | -0.09 | -2.7% | $3.32 | $3.38 | $3.20 | 212,000 | |
| $3.32 | -0.02 | -0.6% | $3.31 | $3.37 | $3.23 | 396,700 | |
| $3.34 | +0.28 | +9.2% | $3.03 | $3.36 | $3.00 | 634,200 | |
| $3.06 | +0.10 | +3.4% | $2.96 | $3.09 | $2.94 | 422,221 | |
| $2.96 | -0.12 | -3.9% | $3.02 | $3.07 | $2.825 | 837,591 | |
| $3.08 | -0.04 | -1.3% | $3.15 | $3.21 | $3.02 | 682,100 | |
| $3.12 | -0.25 | -7.4% | $3.30 | $3.39 | $3.03 | 716,100 |
- Ticker
- NASDAQ:PYXS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium
Latest deck · Sep 9, 2026
Corporate Update (September 2026)
Corporate update · 33 slides
Latest news
Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium
Nov 18, 2026
Closed $1.68 (+19.1%) on Nov 19, 2026
Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)
Nov 5, 2026
Closed $1.61 (-3.0%) on Nov 5, 2026
Pyxis Oncology to Participate in Upcoming Investor Conferences
Oct 28, 2026
Closed $1.98 (+7.6%) on Oct 28, 2026
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Oct 27, 2026
Closed $1.84 (+8.9%) on Oct 27, 2026
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
Oct 2, 2026
Closed $2.14 (-2.3%) on Oct 2, 2026
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
Sep 30, 2026
Closed $2.33 (-19.7%) on Sep 30, 2026
Pyxis Oncology Announces Proposed Public Offering
Sep 29, 2026
Closed $2.33 (-19.7%) on Sep 30, 2026
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
Sep 9, 2026
Closed $3.38 (-13.1%) on Sep 9, 2026
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
Sep 8, 2026
Closed $3.89 (0.0%) on Sep 8, 2026
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Aug 13, 2026
Closed $3.01 (-5.3%) on Aug 13, 2026
Pyxis Oncology, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 83 in all · newest Nov 18, 2026 · oldest 2021
- Decks
- 13 decks · latest Sep 9, 2026
Where Pyxis Oncology, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PYXS · Home listing · This page | NASDAQ | United States | USD |
| BOATS:PYXS | BOATS | United States | USD |
Valuation
Price/book 5.2× against a median of 1.4×: the highest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $160.9M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 5.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.89
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Pyxis Oncology, Inc. · NASDAQ:PYXS | US$216.5M | US$160.9M | n/a | n/a | n/a | 5.2× | n/a | 0.0× | 0.89 |
| Northwest Biotherapeutics, Inc. · OTC:NWBO | US$220.0M | US$283.8M | n/a | 99.4× | n/a | n/a | n/a | n/a | 0.90 |
| Keros Therapeutics, Inc. · NASDAQ:KROS | US$219.7M | −US$24.67M | n/a | −0.6× | n/a | 0.8× | −152.7% | 0.1× | 1.16 |
| Immuneering Corporation · NASDAQ:IMRX | US$218.7M | US$160.5M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.17 |
| Allogene Therapeutics, Inc. · NASDAQ:ALLO | US$217.5M | −US$7.44M | n/a | −1.6× | n/a | 0.6× | n/a | 0.2× | 1.93 |
| ProKidney Corp. · NASDAQ:PROK | US$217.3M | US$77.56M | n/a | 100× | n/a | n/a | n/a | n/a | 1.61 |
| Oryzon Genomics SA · BME:ORY | US$216.4M | US$206.7M | n/a | n/a | n/a | 1.6× | n/a | 0.1× | n/a |
| Rocket Pharmaceuticals, Inc. · NASDAQ:RCKT | US$214.1M | −US$25.02M | n/a | n/a | n/a | 0.7× | n/a | 0.1× | 1.72 |
| Orum Therapeutics, Inc. · KRX:475830 | US$212.5M | US$24.22M | 15.4× | n/a | n/a | 1.5× | n/a | 0.0× | n/a |
| GemVax & KAEL Co Ltd · KRX:082270 | US$212.3M | US$207.4M | n/a | 3.3× | 21.2× | 3.8× | −14.4% | 0.4× | n/a |
| Transgene SA · EURONEXT:TNG | US$212.2M | US$112.7M | n/a | 750× | n/a | 1.8× | n/a | 0.0× | n/a |
| Median of the others | US$216.8M | US$95.15M | 15.4× | 51.3× | 21.2× | 1.4× | −83.5% | 0.1× | 1.39 |
Forecasts
8 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.56 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.13 · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Thomas Civik | Chief Executive Officer and Chairman of the Board |
| Nelson Azoulay | Chief Business Officer |
Board
| Director | Role |
|---|---|
| Thomas Civik | Chief Executive Officer and Chairman of the Board |
| Darren Cline | Director |
| Freda Lewis-Hall | Director |
| Jakob Dupont | Director |
| John Flavin | Lead Independent Director |
| Michael A. Metzger | Director |
| Rachel Humphrey | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −3.0% |
| Q2 2026 | Aug 13, 2026 · Before open | −5.3% |
| Q1 2026 | May 14, 2026 · Before open | −15.7% |
| Q4 2025 | Mar 25, 2026 | +2.2% |
| Q3 2025 | Nov 3, 2025 · Before open | +7.0% |
| Q2 2025 | Aug 14, 2025 · After close | +8.8% |
| Q1 2025 | May 15, 2025 · Before open | +3.7% |
| Q4 2024 | Mar 19, 2025 | +5.7% |
| Q3 2024 | Nov 12, 2024 · Before open | −2.5% |
| Q2 2024 | Aug 14, 2024 · After close | +2.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · Before open | −2.1% |
| Q4 2023 | Mar 21, 2024 · Before open | −8.7% |
| Q3 2023 | Nov 7, 2023 · After close | −1.8% |
| Q2 2023 | Aug 11, 2023 · Before open | +6.6% |
| Q1 2023 | May 11, 2023 · Before open | +2.0% |
| Q4 2022 | Mar 22, 2023 · Before open | 0.0% |
| Q3 2022 | Nov 1, 2022 · Before open | −9.6% |
| Q2 2022 | Aug 15, 2022 · Before open | −4.5% |
| Q1 2022 | May 13, 2022 · Before open | −9.0% |
| Q4 2021 | Mar 29, 2022 · Before open | +0.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (September 2026) | Corporate update | 33 slides | Sep 9, 2026 |
| Investor Presentation (March 2026) | Investor deck | 43 slides | Mar 23, 2026 |
| Corporate Update (December 2025) | Corporate update | 29 slides | Dec 18, 2025 |
| Investor Presentation (November 2025) | Investor deck | 31 slides | Nov 3, 2025 |
| Corporate Update (March 2025) | Corporate update | 29 slides | Mar 18, 2025 |
| Technical Presentation (November 2024) | Technical | 40 slides | Nov 20, 2024 |
| Investor Presentation (March 2024) | Investor deck | 33 slides | Mar 21, 2024 |
| Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022 | Conference | 25 slides | Nov 10, 2022 |
| ASCO 2022 | Conference | 14 slides | June 2022 |
| Technical Presentation (April 2022) | Technical | 21 slides | April 2022 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (December 2020) | Technical | 10 slides | December 2020 |
| AACR Annual Meeting 2019 | Conference | 25 slides | Mar 31, 2019 |
| SITC 32nd Annual Meeting 2017 | Conference | 19 slides | November 2017 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock or pre-funded warrants with accompanying common warrants Closed: US$110M raised · US$2.9 a share · Warrants at US$3.5 · Leerink Partners +2 Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Wells Fargo Securities (co-lead) Buyers: OrbiMed; GordonMD Global Investments; BVF Partners; Coastlands Capital; RTW Investments Use of proceeds: Advance lead program MICVO through key clinical milestones including planned Phase 3 Headliner trial, plus working capital and general corporate purposes | Oct 2, 2026 |
| Private placement of securities with accompanying warrants Closed: US$50M raised Use of proceeds: Advance MICVO through key clinical milestones and continue patient follow-up so data can mature | Aug 13, 2026 |
| Private placement of common stock and warrants Announced: about US$50M · US$2.551 a share · Warrants at US$3.289 · Wells Fargo Securities Dealers: Wells Fargo Securities (lead) Buyers: BVF Partners L.P. (led the financing); GordonMD Global Investments; RTW Investments; Coastlands Capital Use of proceeds: Extend cash runway into Q2 2027 and advance lead clinical program MICVO through key clinical milestones | Jun 30, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Oct 7, 2021.
- Price
- US$16.00 a share
- Shares offered
- 10,500,000 shares of common stock
- Offering size
- US$168 million
- Underwriters' option
- Up to 1,575,000 more shares
- Underwriters
- BofA Securities, Jefferies, Credit Suisse, William Blair, LifeSci Capital · In the order on the cover
- Shares delivered
- On or about Oct 13, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 21, 2021 |
| Filed publicly | Sep 17, 2021 |
| Amended 3 times | Newest Oct 7, 2021 |
| Shares registered with an exchange | Oct 5, 2021 |
| Declared effective by the SEC | Oct 7, 2021 |
| Final prospectus, with the price | Oct 8, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 8, 2021 |
| EFFECT · Notice that a registration is effective | Oct 7, 2021 |
| S-1MEF · Registration of more shares for the same offering | Oct 7, 2021 |
| S-1/A · Registration statement, amended | Oct 7, 2021 |
| CERT · Exchange's certificate of listing | Oct 6, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 5, 2021 |
| CORRESP · Letter to the SEC | Oct 5, 2021 |
| CORRESP · Letter to the SEC | Oct 5, 2021 |
| S-1/A · Registration statement, amended | Oct 4, 2021 |
| S-1/A · Registration statement, amended | Oct 1, 2021 |
All 19 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Sep 28, 2021 |
| S-1 · Registration statement | Sep 17, 2021 |
| DRS/A · Draft registration statement, amended | Sep 10, 2021 |
| DRSLTR · Letter to the SEC with a draft | Sep 9, 2021 |
| UPLOAD · Letter from the SEC | Aug 18, 2021 |
| DRSLTR · Letter to the SEC with a draft | Aug 4, 2021 |
| DRS/A · Draft registration statement, amended | Aug 4, 2021 |
| UPLOAD · Letter from the SEC | Jul 16, 2021 |
| DRS · Draft registration statement | Jun 21, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 8, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 13.9M | 16.1M | ||||
| Cost of revenue | 2.39M | 475.0K | ||||
| Gross profit | 11.5M | 15.7M | ||||
| Research and development | 73.7M | 58.7M | 49.6M | 86.1M | 51.1M | 9.05M |
| Operating income | -84.4M | -89.5M | -82.2M | -123.5M | -69.7M | -12.9M |
| Depreciation and amortization | 4.51M | 2.98M | 1.93M | 709.0K | 647.0K | 469.0K |
| EBITDA | -79.9M | -86.5M | -80.3M | -122.8M | -69.1M | -12.4M |
| Income before tax | -78.2M | -79.5M | -73.8M | |||
| Income tax | 1.39M | -2.16M | ||||
| Net income | -79.6M | -77.3M | -73.8M | -120.7M | -76.0M | -12.8M |
| Earnings per share, basic | -1.28 | -1.32 | -1.85 | -3.65 | -8.95 | -12.45 |
| Earnings per share, diluted | -1.28 | -1.32 | -1.85 | -3.65 | -8.95 | -12.45 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 15.4M | 19.5M | 9.66M | 179.3M | 274.7M | 8.08M |
| Short-term investments | 51.4M | 107.5M | 109.6M | |||
| Current assets | 72.1M | 132.4M | 124.6M | 186.6M | 278.7M | 8.10M |
| Property, plant and equipment | 8.00M | 9.90M | 11.9M | 11.2M | 1.01M | 1.10M |
| Total assets | 91.5M | 157.2M | 173.7M | 211.4M | 280.0M | 10.2M |
| Accounts payable | 10.9M | 4.86M | 3.90M | 7.10M | 12.0M | 1.08M |
| Current liabilities | 21.1M | 17.7M | 25.8M | 31.6M | 18.7M | 3.69M |
| Total liabilities | 38.1M | 36.4M | 48.0M | 50.6M | 18.7M | 3.85M |
| Shareholders' equity | 53.4M | 120.8M | 125.7M | 160.8M | 261.3M | -15.6M |
| Shares outstanding | 62.7M | 60.0M | 44.8M | 35.0M | 32.2M | 1.29M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -63.5M | -57.7M | -70.7M | -89.3M | -35.3M | -10.1M |
| Capital spending | -9.00K | -237.0K | -6.73M | -6.40M | -540.0K | -1.48M |
| Free cash flow | -63.5M | -57.9M | -77.4M | -95.7M | -35.9M | -11.6M |
| Cash from investing | 58.9M | 8.15M | -104.8M | -6.40M | -590.0K | -1.48M |
| Cash from financing | 594.0K | 59.3M | 5.93M | 183.0K | 304.0M | 35.0K |
| Change in cash | -4.05M | 9.81M | -169.6M | -95.6M | 268.1M | -11.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 19, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 3, 2026 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Oct 21, 2026 | Meeting notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| PRE 14A · Preliminary proxy statement | Oct 9, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 9, 2026 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Oct 9, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 2, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 1, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Oct 1, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Sep 29, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Sep 29, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2026 | Management or board change | SEC |
| 424B2 · Prospectus | Aug 28, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 28, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| S-3 · Registration statement | Aug 20, 2026 | Offer document | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 3 · Initial statement of ownership | Jul 10, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 2, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 2, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 15, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 8-K/A · Current report, amended | Apr 30, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 23, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 23, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 23, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 9, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 18, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 8, 2025 | Other filings | SEC |
| S-3 · Registration statement | Nov 26, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 3, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 23, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 8-K · Current report | Aug 4, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 2, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 1, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 18, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 14, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 2, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 24, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 18, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 18, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 18, 2025 | Results | SEC |
| 8-K · Current report | Feb 26, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 4, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 4, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 23, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 19, 2024 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 16, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 20, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Nov 12, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 6, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 23, 2024 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Sep 25, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Sep 13, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 8-K · Current report | Jun 12, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 4, 2024 | Other filings | SEC |
| 424B2 · Prospectus | Apr 3, 2024 | Offer document | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 3, 2024 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Apr 1, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 29, 2024 | Other filings | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| S-3 · Registration statement | Mar 27, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 27, 2024 | Current report | SEC |
| 8-K · Current report | Mar 27, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 21, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 21, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 21, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 13, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 13, 2024 | Management or board change | SEC |
| SC 13G · Big-stake notice | Mar 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 28, 2024 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jan 26, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 30, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 28, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2023 | Results | SEC |
| 8-K/A · Current report, amended | Oct 27, 2023 | Current report | SEC |
| 4 · Change in ownership | Sep 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 18, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 14, 2023 | Other filings | SEC |
| 4 · Change in ownership | Sep 13, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 13, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 12, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2023 | Other filings | SEC |
| 4 · Change in ownership | Sep 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2023 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Sep 6, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 5, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 28, 2023 | Other filings | SEC |
| 4 · Change in ownership | Aug 25, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 25, 2023 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 25, 2023 | Other filings | SEC |
| S-8 POS | Aug 23, 2023 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Aug 23, 2023 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Aug 23, 2023 | Offer document | SEC |
| 8-K · Current report | Aug 23, 2023 | Acquisition or disposal | SEC |
| UPLOAD · Letter from the SEC | Aug 16, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 11, 2023 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| 425 | Aug 11, 2023 | Other filings | SEC |
| 8-K · Current report | Aug 11, 2023 | Results | SEC |
| 425 | Aug 11, 2023 | Other filings | SEC |
This page holds 200 of 362 filings. Open Filings
Cap table
Built by 6ix from Pyxis Oncology, Inc.’s releases · as of Nov 4, 2026
- Common shares
- 119,607,855
- Fully diluted
- 119,607,855
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 119,607,855 | Nov 4, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$3.50 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 4, 2026 | 119,607,855 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Freda Lewis-Hall Other companies: CDT Equity Inc. (Director · Since at least Sep 22, 2023); SpringWorks Therapeutics Inc (Director · Since at least Mar 29, 2019); EXACT Sciences Corporation (Director · Apr 22, 2020 – Jun 8, 2023 · Past); 1Life Healthcare Inc (Director · Jan 30, 2020 – Feb 22, 2023 · Past); Pfizer, Inc. (Executive Vice President · Feb 22, 2018 – Feb 27, 2019 · Past) | Director · Since at least Oct 7, 2021 |
| Darren Cline Other companies: Xenon Pharmaceuticals Inc. (Chief Commercial Officer · Since at least Jun 23, 2025); Pliant Therapeutics, Inc. (Board Member · Since at least Jun 13, 2024) | Director · Since at least Mar 26, 2024 |
| Rachel Humphrey Other companies: Xilio Therapeutics, Inc. (Director · Oct 21, 2021 – Oct 21, 2021 · Past); Black Diamond Therapeutics, Inc. (Chief Medical Officer · Feb 17, 2021 – Feb 17, 2021 · Past) | Director · Since at least Aug 11, 2022 |
| John Flavin Other companies: Advanced Life Sciences Holdings Inc (President /Chief Financial Off, Director · Mar 10, 2006 – Aug 16, 2010 · Past) | Lead Independent Director · Since at least Oct 7, 2021 |
| Michael A. Metzger Other companies: Syndax Pharmaceuticals, Inc. (Chief Executive Officer and Director · Since at least Jul 16, 2025) | Director · Since at least Mar 31, 2025 |
| Santhosh Palani Other companies: Acrivon Therapeutics, Inc. (Director · Since at least Mar 4, 2024) | Director · Since at least Mar 12, 2024 |
| Thomas Civik Other companies: Repare Therapeutics Inc (Director · Since at least Jun 17, 2024) | Chief Executive Officer and Chairman of the Board · Since at least Mar 26, 2024 |
| Alex Kane | Senior Vice President, Investor Relations & Capital Markets · Oct 9, 2025 – Nov 5, 2026 · Past |
| Jakob Dupont | Director · Since at least Jul 2, 2026 |
| Jay Feingold | Chief Medical Officer · Oct 7, 2021 – Mar 24, 2023 · Past |
All 16 people
| Person | Seat |
|---|---|
| Jitendra Wadhane | Prin Fin & Acct Officer · Since at least Aug 3, 2022 |
| Joel Edwards | Chief Business Officer · Oct 1, 2025 – Nov 5, 2026 · Past |
| Ken Kobayashi | Chief Medical Officer · Nov 27, 2023 – Dec 29, 2023 · Past |
| Nelson Azoulay | Chief Business Officer · Since at least May 7, 2026 |
| Pyxis Oncology ContactPamela Connealy | CFO and COO · Feb 4, 2025 – Nov 5, 2026 · Past |
| Ronald Herbst | Chief Scientific Officer · Oct 7, 2021 – Oct 7, 2021 · Past |
Log in to ask 6ix AI your own questions about Pyxis Oncology, Inc.